|
|
|
| Application of Gene Testing-Guided Individualized Medication in Patients with Primary Hypertension |
| WU Fan, JIA Yadan, ZHAI Huaji, MA Xiaobiao, HE Xiuhua |
| Department of Cardiology, Xuchang Central Hospital, Xuchang Henan 461000 |
|
|
|
|
Abstract 【Objective】 To investigate the application of gene testing-guided individualized medication in patients with primary hypertension. 【Methods】 A total of 164 patients with primary hypertension admitted to our hospital from June 2023 to June 2025 were enrolled and randomly divided into a control group and an observation group, with 82 patients in each group. Patients in the control group received conventional antihypertensive therapy, while those in the observation group received gene testing-guided individualized medication. Clinical efficacy, blood pressure control [systolic blood pressure (SBP), diastolic blood pressure (DBP), and blood pressure control rate], treatment adherence [Hypertension Treatment Adherence Scale], and the incidence of adverse reactions were compared between the two groups. 【Results】 The total effective rate in the observation group was higher than that in the control group, with a statistically significant difference (P<0.05). After treatment, systolic blood pressure (SBP) and diastolic blood pressure (DBP) in the observation group were lower than those in the control group, and the blood pressure compliance rate was higher than that in the control group, with statistically significant differences (P<0.05). After treatment, the scores of medication compliance behavior, avoidance of inappropriate medication behavior, management of daily living activities, smoking and alcohol habit management behavior, as well as the total compliance score in both groups were higher than those before treatment. The observation group had higher scores of medication compliance behavior, avoidance of inappropriate medication behavior and total compliance score than the control group, with a statistically significant difference (P<0.05). The total incidence of adverse reactions in the observation group was lower than that in the control group, with a statistically significant difference (P<0.05). 【Conclusion】 Gene testing-guided individualized medication can significantly improve blood pressure control, enhance treatment adherence, and reduce drug-related adverse reactions in patients with primary hypertension, demonstrating high clinical application value.
|
|
Received: 26 December 2025
|
|
|
|
|
|
[1] 苏鸿,代时玉,武婷婷. 厄贝沙坦氢氯噻嗪联合他汀类制剂治疗原发性高血压的效果[J].中外医学研究,2025,23(20):43-46.
[2] 王姣,郎月,崔婷婷,等. 奥美沙坦酯氨氯地平片治疗老年原发性高血压的临床疗效及安全性[J].医学临床研究,2025,42(7):1257-1259.
[3] 张彦伟,陈明远,赵俊康. 山西省高血压病人降压药物相关基因多态性分布[J].护理研究,2023,37(9):1656-1658.
[4] 冯淳,甄拴平,王华,等. 降压药物基因多态性在高血压患者中的分布[J].检验医学与临床,2023,20(22):3290-3296.
[5] 万淑君,张梦莹,陈其雷,等. 高血压药物基因多态性分析对安徽皖南地区高血压患者个体化治疗的参考价值[J].中国临床药理学与治疗学,2024,29(1):68-75.
[6] 中国高血压防治指南修订委员会, 高血压联盟(中国),中国医疗保健国际交流促进会高血压分会,等.中国高血压防治指南(2024年修订版)[J].中华高血压杂志,2024,32(7):603-700.
[7] 唐红英,朱京慈,何海燕,等. 高血压治疗依从性量表的编制及信效度研究[J].第三军医大学学报,2011,33(13):1400-1403.
[8] 冯琦,赵程龙,刘敬宇,等. 不同降压药物治疗原发性高血压的药物经济学研究进展[J].中国药物经济学,2025,20(2):104-107.
[9] 张愉,吕尚军,权青云,等. 西安地区306例原发性高血压患者与降压药物相关的基因多态性分布特征分析[J].现代检验医学杂志,2024,39(3):90-97.
[10] 罗璇,王见勇. 常德地区原发性高血压患者基因型与降压药物基因多态性的关系及其精准用药分析[J].临床合理用药,2025,18(3):44-48.
[11] 任爽,李洋,王凯. 老年高血压患者个体化用药风险基因分析[J].河北医药,2023,45(1):39-43.
[12] 易珍奎,李建容,谭安军. 538例高血压患者的药物基因多态性与精准用药分析[J].中国处方药,2024,22(1):69-72.
[13] 高亭艳,朱平辉,王军. 高血压基因导向个体化用药在老年高血压患者中的应用效果[J].心肺血管病杂志,2022,41(12):1248-1252.
[14] 叶章正,李世阁,张晓丹,等. 基因检测指导下个体化用药治疗对3级高血压患者的治疗效果及不良反应分析[J].中国循证心血管医学杂志,2025,17(4):499-502. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(7): 1257-1259. |
|
|
|
|
2026, Vol. 43 
